A Medication Trial Combined With Behavior Therapy for Individuals With Obsessive-compulsive Disorder
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study examines the efficacy of the medication D-Cycloserine in the reduction of obsessions and compulsions in individuals with obsessive-compulsive disorder (OCD). All study participants will receive Exposure and Response Prevention, a common form of behavior therapy for individuals with OCD. Half (50%) of the participants will be randomly assigned to the placebo condition and the other half (50%) will be randomly assigned to receive D-Cycloserine. Because all participants will receive 10 sessions of behavior therapy, all participants are expected to improve from this treatment.
| Condition | Intervention |
|---|---|
|
Obsessive-Compulsive Disorder |
Behavioral: behavior therapy Drug: D-Cycloserine |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-blind, Placebo-controlled Medication Trial With D-Cycloserine for Individuals With Obsessive-compulsive Disorder Currently Receiving Behavior Therapy |
- significant reduction of OCD symptoms after the completion of treatment
- significant reduction of depressive symptoms after the completion of treatment
| Estimated Enrollment: | 50 |
| Study Start Date: | December 2003 |
| Study Completion Date: | December 2007 |
The study consists of Behavior Therapy (Exposure and Response Prevention; ERP) for OCD. Specifically, it involves exposure to anxiety-provoking situations and response-prevention of any rituals. ERP has shown to be effective for many individuals with OCD.
All assessments and treatment sessions are at no cost to the patients. 50% of the patients will randomly be assigned to the D-Cycloserine (DCS) condition, and 50% of the patients will be assigned to a placebo condition. D-Cycloserine is FDA-approved for the treatment of Tuberculosis. However, recent research in other anxiety disorders has shown that D-Cycloserine plus Behavior Therapy is more effective than Behavior Therapy alone.
This treatment study has two active conditions. That is, all patients will receive Behavior Therapy and we do expect that everybody will improve from this treatment. However, it may be that those patients in the DCS condition will improve somewhat more than those in the placebo condition.
The treatment will be structured with homework and repeated assessments every 4 weeks. Assessments are extremely important as they guide the treatment and provide the study investigators necessary information about the treatment. The treatment consists of 10 sessions (twice a week) plus post-treatment and follow-up assessments at 1 and 6 months.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Meets diagnosis for obsessive-compulsive disorder
Exclusion Criteria:
- History of psychotic disorders
- History of neurological disorders
- History of bipolar disorders
Contacts and Locations| United States, Connecticut | |
| Anxiety Disorders Center, The Institute of Living | |
| Hartford, Connecticut, United States, 06106 | |
| United States, Massachusetts | |
| Massachusetts General Hospital | |
| Boston, Massachusetts, United States, 02114 | |
| Principal Investigator: | Sabine Wilhelm, PhD | Massachusetts General Hospital |
| Principal Investigator: | David Tolin, PhD | Hartford Institute of Living |
More Information
Additional Information:
No publications provided
| Responsible Party: | Sabine Wilhelm, Ph.D., Massachusetts General Hospital |
| ClinicalTrials.gov Identifier: | NCT00126282 History of Changes |
| Other Study ID Numbers: | 2003-P-0001325 |
| Study First Received: | August 2, 2005 |
| Last Updated: | July 27, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Massachusetts General Hospital:
|
obsessive-compulsive disorder behavior therapy D-Cycloserine medication |
treatment trial placebo-controlled double-blind randomized |
Additional relevant MeSH terms:
|
Obsessive-Compulsive Disorder Anxiety Disorders Mental Disorders Cycloserine Anti-Infective Agents, Urinary Anti-Infective Agents Therapeutic Uses |
Pharmacologic Actions Renal Agents Antibiotics, Antitubercular Anti-Bacterial Agents Antitubercular Agents Antimetabolites Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 23, 2013